Skip to main content

Table 2 Time spent receiving each treatment during PD health state

From: Cost effectiveness analysis of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small-cell lung cancer from the Singapore healthcare payer’s perspective

 

Afatinib arm

Pemetrexed-cisplatin arm

Estimated total time in PD, months

21.17a

23.92a

Mean time receiving second-line treatment, months

5.40c

11.90d

Mean time receiving third-line treatment (BSC), months

15.77b

12.02b

  1. PD progressive disease
  2. aFrom partitioned survival model
  3. bTime in BSC = time in PD – time in second-line
  4. Source: c Soria et al, [13]; dKim et al, [14]
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us